Komal Jhaveri, MD, FACP on The Phase III EMBER Trial
At the San Antonio Breast Cancer Symposium, Komal Jhaveri, MD, FACP, presented results of the phase III EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader as monotherapy and combined with abemaciclib for patients with ER+/HER2-negative advanced breast cancer. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Speaker 1: At the San Antonio Breast Cancer meeting this year, I had the opportunity to present the results from the Phase III
